申请人:Samjin Pharmaceutical Co., Ltd.
公开号:US20020111491A1
公开(公告)日:2002-08-15
The present invention relates to new 9-aminoacridine derivatives of general formula (I), wherein A is hydrogen or (II) (wherein X is oxygen or sulfur, R
1
, R
2
, R
3
, R
4
and R
5
are independently hydrogen, halogen, nitro, amino, hydroxy, C
1
-C
4
lower alkylhydroxy, C
1
-C
4
lower alkylamino, C
1
-C
8
alkyl, C
1
-C
4
lower alkoxy or C
1
-C
4
lower alkyloxycarbonyl and m and n are independently an integer of 0, 1 or 2), R
6
, R
7
, R
8
and R
9
are independently C
1
-C
8
alkyl or C
1
-C
4
lower alkoxy, and Y is hydrogen, amino, -N═CHR′(wherein R′ is hydrogen, benzyl, C
1
-C
8
alkyl or C
1
-C
6
lower alkylamino), (III) (wherein R″ is hydrogen, benzyl, C
1
-C
8
alkyl or C
1
-C
6
lower alkylamino, and R′″ is hydrogen, benzyl, C
1
-C
8
alkyl or amino protecting group) or (IV) (wherein, X is as defined above, R
1
′, R
2
′, R
3
′, R
4
′ and R
5
′ are independently hydrogen, halogen, nitro, amino, hydroxy, C
1
-C
4
lower alkylhydroxy, C
1
-C
4
lower alkylamino, C
1
-C
8
alkyl, C
1
-C
4
lower alkoxy or C
1
-C
4
lower alkylcarboxy, and q and r are independently an integer of 0, 1 or 2) or its pharmaceutically acceptable salt, and process for the preparation thereof.
本发明涉及通式(I)的新9-氨基蒽衍生物,其中A为氢或(II)(其中X为氧或硫,R1、R2、R3、R4和R5独立地为氢、卤素、硝基、氨基、羟基、C1-C4较低烷基羟基、C1-C4较低烷基氨基、C1-C8烷基、C1-C4较低烷氧基或C1-C4较低烷氧羰基,m和n独立地为0、1或2的整数),R6、R7、R8和R9独立地为C1-C8烷基或C1-C4较低烷氧基,Y为氢、氨基、-N═CHR′(其中R′为氢、苄基、C1-C8烷基或C1-C6较低烷基氨基)、(III)(其中R″为氢、苄基、C1-C8烷基或C1-C6较低烷基氨基,R′″为氢、苄基、C1-C8烷基或氨基保护基)或(IV)(其中,X如上定义,R1′、R2′、R3′、R4′和R5′独立地为氢、卤素、硝基、氨基、羟基、C1-C4较低烷基羟基、C1-C4较低烷基氨基、C1-C8烷基、C1-C4较低烷氧基或C1-C4较低烷基羧基,q和r独立地为0、1或2)或其药学上可接受的盐,以及其制备方法。